Replies to post #154675 on Biotech Values

[mcbio]

I haven't checked to see the dose and how the safety of the Pharmacopoeia/Ligand was in trials so could turn out to not be an issue.

Check slide 18 of the Retrophin corporate presentation I referenced before (can't link it as it's an Adobe file but it's on the Web site as I described). That slide discusses ERAs and edema and compares safety of RE-021 from Phase 2b trial to that of avosentan and darusentan Phase 3 trial data (the latter two seemed to show much greater issues with edema in the clinic compared to RE-021).